Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications

Rosie Bell, Michele VendruscoloFrontiers in Neurology 2021 · DOI

Abstract

Parkinson's disease is characterised by the presence in brain tissue of aberrant inclusions known as Lewy bodies and Lewy neurites, which are deposits composed by α-synuclein and a variety of other cellular components, including in particular lipid membranes. The dysregulation of the balance between lipid homeostasis and α-synuclein homeostasis is therefore likely to be closely involved in the onset and progression of Parkinson's disease and related synucleinopathies. As our understanding of this balance is increasing, we describe recent advances in the characterisation of the role of post-translational modifications in modulating the interactions of α-synuclein with lipid membranes. We then discuss the impact of these advances on the development of novel diagnostic and therapeutic tools for synucleinopathies.

Introduction

Parkinson’s disease (PD) is traditionally viewed as a "proteinopathy" defined by the aggregation of $\alpha$-synuclein ($\alpha$-syn) into Lewy bodies. However, emerging evidence suggests it is equally a "lipidopathy." In a healthy brain, $\alpha$-syn is essential for normal synaptic function, particularly in regulating the homeostasis of synaptic vesicles. This review, published in Frontiers in Neurology, synthesizes a decade of research into how the "molecular decorations"—post-translational modifications (PTMs)—on $\alpha$-syn determine its behavior at the surface of cellular membranes.

The Synaptic Role of α-Synuclein

In its physiological state, $\alpha$-syn binds to synaptic vesicles to regulate neurotransmitter release. This interaction is not static; the protein transitions from a disordered cytosolic state to an $\alpha$-helical structure upon membrane binding.

Figure 1: The physiological role of α-synuclein within the synapse, where it interacts with synaptic vesicles to regulate processes such as dopamine synthesis, vesicle clustering, and neurotransmitter release.

As illustrated in Figure 1, $\alpha$-syn is deeply integrated into the synaptic machinery, influencing everything from vesicle clustering to the assembly of the SNARE complex. Disruptions to this balance are a primary driver of neurodegeneration.

Methodological Approaches to Protein-Lipid Interactions

To unravel these complex interactions, researchers employ a suite of biophysical and biochemical tools. Nuclear Magnetic Resonance (NMR) and Circular Dichroism (CD) are used to observe the structural transition of $\alpha$-syn from a disordered "floppy" state to an $\alpha$-helical state upon membrane contact. Fluorescence assays, utilizing amyloid-binding dyes like Thioflavin T, track aggregation kinetics in the presence of different lipid compositions. Furthermore, advances in synthetic protein chemistry now enable the creation of "semisynthetic" $\alpha$-syn variants, allowing scientists to study the effects of specific PTMs at precise locations—a feat difficult to achieve with standard cellular expression systems.

The Transition to Toxicity: A Lipid-Protein Interplay

The central challenge in PD research is understanding why $\alpha$-syn turns toxic in some cellular contexts but not others. PTMs function as molecular switches that tune the protein's affinity for lipids, its shape, and its tendency to aggregate.

Figure 3: A conceptual map showing the balance between the biological function of α-synuclein and its transition toward toxic aggregation (oligomers, fibrils, and Lewy bodies), mediated by PTMs and membrane binding.

Figure 3 highlights the dual nature of these interactions. While membrane binding is necessary for function, lipid surfaces can also act as platforms for primary nucleation—the first step in the formation of toxic clumps. PTMs can either stabilize the functional state or accelerate the path toward Lewy body formation.

The PTM Code: Molecular Switches of Aggregation

The review identifies several critical PTMs that dictate $\alpha$-syn behavior:

  • N-terminal Acetylation: Constitutive in the human brain, this modification increases membrane affinity and may be protective against aggregation.
  • Phosphorylation at Ser129 (pS129): While a hallmark of PD, its direct effect on membrane binding is minimal, suggesting its role lies in downstream signaling or clearance.
  • Nitration: Often occurring under oxidative stress, nitration (particularly at Y39) reduces membrane binding and can lead to toxic cross-linking.
  • Truncation: Losing the C-terminal tail makes $\alpha$-syn aggregate an order of magnitude faster in the presence of lipids, as the C-terminus normally shields the aggregation-prone NAC region.
  • O-GlcNAcylation: This "sugar-coating" generally inhibits aggregation and toxicity, potentially competing with more harmful modifications like phosphorylation.

Conclusion and Future Perspectives

Understanding the modulation of $\alpha$-syn-lipid interactions by PTMs offers a roadmap for developing high-precision biomarkers and "lipid-aware" therapies. Future work must move beyond simple model membranes to study these interactions in the complex lipid environment of the neuron and investigate the "crosstalk" between different PTMs. By targeting the specific modifications that drive toxicity, we may unlock new ways to restore the healthy balance of $\alpha$-syn in the brain.

Summary updated

Abstract

Parkinson's disease is characterised by the presence in brain tissue of aberrant inclusions known as Lewy bodies and Lewy neurites, which are deposits composed by α-synuclein and a variety of other cellular components, including in particular lipid membranes. The dysregulation of the balance between lipid homeostasis and α-synuclein homeostasis is therefore likely to be closely involved in the onset and progression of Parkinson's disease and related synucleinopathies. As our understanding of this balance is increasing, we describe recent advances in the characterisation of the role of post-translational modifications in modulating the interactions of α-synuclein with lipid membranes. We then discuss the impact of these advances on the development of novel diagnostic and therapeutic tools for synucleinopathies.
BibTeX
@inproceedings{bell2021modulation,
  author = {Rosie Bell and Michele Vendruscolo},
  title = {{Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications}},
  booktitle = {Frontiers in Neurology},
  year = {2021},
  doi = {10.3389/fneur.2021.661117},
}
Figure